BLU Share Price

Open 0.39 Change Price %
High 0.40 1 Day 0.02 5.26
Low 0.39 1 Week 0.00 0.00
Close 0.40 1 Month 0.00 0.00
Volume 38728 1 Year 0.06 17.65
52 Week High 0.55
52 Week Low 0.21
BLU Important Levels
Resistance 2 0.41
Resistance 1 0.41
Pivot 0.40
Support 1 0.39
Support 2 0.39
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
CVE 9.55 4.37%
CVE 9.55 4.37%
CVE 9.55 4.37%
SC 60.83 -0.44%
More..
TSE Canada Top Gainers Stocks
CAL 8.00 384.85%
CAL 8.00 384.85%
CAL 8.00 384.85%
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
AAB 0.14 16.67%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
CTU-A 0.19 -9.52%
BNG 0.10 -9.09%
BNG 0.10 -9.09%
HCG 16.22 -8.57%
HCG 16.22 -8.57%
HCG 16.22 -8.57%
HCG 16.22 -8.57%
DEJ 0.14 -6.67%
DEJ 0.14 -6.67%
More..

BELLUS Health, Inc. (TSE: BLU)

BLU Technical Analysis 3
As on 27th Jun 2017 BLU Share Price closed @ 0.40 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.29 & Buy for SHORT-TERM with Stoploss of 0.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
BLU Target for June
1st Target up-side 0.55
2nd Target up-side 0.65
3rd Target up-side 0.75
1st Target down-side 0.25
2nd Target down-side 0.15
3rd Target down-side 0.05
BLU Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bellushealth.com
BLU Address
BLU
275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
Canada
Phone: 450-680-4500
Fax: 450-680-4501
BLU Latest News
BELLUS Health Inc (BLU.TO) Ichimoku Reveals Positive Momentum   Concord Register   - 25th Jun 17
BELLUS Health announces sale of its equity interest in FB Health for total ...   Canada NewsWire (press release)   - 19th Jun 17
Pharmascience disposes of securities of BELLUS Health Inc.   Canada NewsWire (press release)   - 06th Jun 17
BRIEF-Bellus Health to sell subsidiary Thallion Pharmaceuticals to Taro ...   Reuters   - 17th Mar 17
BRIEF-Bellus Health and the NEOMED Institute announce agreement for ...   Reuters   - 28th Feb 17
BELLUS Health provides update on pipeline   Canada NewsWire (press release)   - 21st Dec 16
Bellus Health: Phase 3 Results of Kiacta for AA Amyloidosis   Drug Discovery & Development   - 21st Jun 16
Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 ...   GlobeNewswire (press release)   - 21st Jan 16
BELLUS Health: Results From KIACTA Phase 3 Clinical Trial Expected In Mid-2016   Seeking Alpha   - 18th Nov 15
Bellus Health Developing Shigamab For The Treatment Of STEC-HUS   Seeking Alpha   - 07th Oct 15
Interactive Technical Analysis Chart BELLUS Health, Inc. ( BLU TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BELLUS Health, Inc.
BLU Business Profile
BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. Its clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome related to shiga toxin-producing E. coli bacterial infections. The company also has an agreement with AmorChem Holdings Inc. to develop drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.